Genzyme Molecular Oncology Division definition

Genzyme Molecular Oncology Division means, at any time, the Corporation's interest in (i) the following businesses, products, or development or research programs: (A) the use of the Serial Analysis of Gene Expression ("SAGE") technology licensed from Johns Hopkins University School of Medicine for third parties; (B) the clinical program developing adenovirus vectors containing the tumor antigens MART 1 or gp100 for treatment of melanoma: (C) the "suicide" gene therapy research program developing adenovirus and lipid vectors containing genes to enhance chemotherapy for oncology indications; (D) the research
Sample 1Sample 2Sample 3
Genzyme Molecular Oncology Division means, at any time, the Corporation's interest in (i) the following businesses, products, or development or research programs: (A) the use of the Serial Analysis of Gene Expression ("SAGE") technology licensed from Johns Hopkins University School of Medicine for third parties; (B) the clinical program developing adenovirus vectors containing the tumor antigens MART 1 or gp100 for treatment of melanoma: (C) the "suicide" gene therapy research program developing adenovirus and lipid vectors containing genes to enhance chemotherapy for oncology indications; (D) the research program developing adenovirus and lipid vectors containing tumor suppressor genes for oncology indications; (E) the research program developing adenovirus and lipid containing genes to regulate the immune system for oncology indications, including heat shock proteins; (F) the research program developing antibody-targeted gene therapy for treatment of tumors; (G) the research program developing small molecule compounds to inhibit angiogenesis and stimulate apoptosis; (H) the research program developing small molecule compounds to regulate tumor
Sample 1

Examples of Genzyme Molecular Oncology Division in a sentence

  • Genzyme Corporation reports earnings per share based on its four tracking stocks - Genzyme General Division Common Stock ("GENZ Stock"), Genzyme Surgical Products Division Common Stock ("GZSP Stock"), Genzyme Molecular Oncology Division Common Stock ("GZMO Stock") and Genzyme Tissue Repair Division Common Stock ("GZTR Stock").

  • Forty million (40,000,000) shares of Common Stock are designated as a series of Common Stock with the following designation: Genzyme Molecular Oncology Division Common Stock (the "GMO Stock").

  • As independent public accountants, we hereby consent to the incorporation by reference in this registration statement on Form S-3 of Genzyme Corporation to register 452,915 shares of Genzyme Molecular Oncology Division Common Stock of our report dated March 3, 1997 relating to the financial statements of PharmaGenics, Inc.

  • We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Genzyme Corporation for its 1997 Equity Incentive Plan of our reports dated February 23, 1999 related to the financial statements and financial statement schedules of Genzyme Corporation, Genzyme General Division, Genzyme Tissue Repair Division and Genzyme Molecular Oncology Division, which appear in Genzyme Corporation's 1998 Annual Report on Form 10-K.

  • Of the Genzyme Common Stock, as of the date of this Agreement, 500,000,000 shares have been designated Genzyme General Division Common Stock (“Parent Common Stock”), 100,000,000 shares have been designated Genzyme Biosurgery Division Common Stock (“GBX Common Stock”), 40,000,000 shares have been designated Genzyme Molecular Oncology Division Common Stock, $0.01 par value per share (“GMO Common Stock”) and 50,000,000 shares have been undesignated as to series.

  • The Putnam Voyager Fund, Genzyme General Division Common Stock Fund, Genzyme Tissue Repair Division Common Stock Fund and Genzyme Molecular Oncology Division Common Stock Fund are stated at fair value, based upon quoted market prices in an active market on the last business day of the Plan year.

  • SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) FINANCIAL INFORMATION Genzyme will provide to holders of Genzyme Molecular Oncology Division Common Stock ("GMO Stock") separate financial statements, management's discussion and analysis, descriptions of business and other relevant information for GMO.

  • Net loss for Genzyme Molecular Oncology Division for the three months ended March 31, 1999 was $(7,060) or $(0.56) per basic and diluted share of GZMO Stock.

  • The Registration Statement relates to 33,600 shares of Genzyme General Division Common Stock, $0.01 par value, 30,000 shares of Genzyme Tissue Repair Division Common Stock, $0.01 par value, and 70,000 shares of Genzyme Molecular Oncology Division Common Stock, $0.01 par value (collectively, the "Shares"), offered pursuant to the provisions of the Company's 1988 Director Stock Option Plan (the "Plan").

  • Genzyme provides separate financial statements for the Company and its subsidiaries on a consolidated basis and for each of Genzyme General, Genzyme Surgical Products Division ("Genzyme Surgical Products" or "GSP"), Genzyme Molecular Oncology Division ("Genzyme Molecular Oncology" or "GMO") and Genzyme Tissue Repair Division ("Genzyme Tissue Repair" or "GTR").

Related to Genzyme Molecular Oncology Division

  • Clinical laboratory means a facility for the microbiological, serological, chemical, hematological, radiobioassay, cytological, immunohematological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of a disease or assessment of a medical condition.

  • BMS means the Company, all related companies, affiliates, subsidiaries, parents, successors, assigns and all organizations acquired by the foregoing.

  • Novartis shall have the meaning set forth in the Preamble.

  • Merck has the meaning set forth in the preamble.

  • Clinical peer means a physician or other health care professional who holds a non-restricted license in a state of the United States and in the same or similar specialty as typically manages the medical condition, procedure or treatment under review.

  • Clinical means having a significant relationship, whether real or potential, direct or indirect, to the actual rendering or outcome of dental care, the practice of dentistry, or the quality of dental care being rendered to a patient;

  • PTC means the tax credit for electricity produced from certain renewable generation resources described in Section 45 of the Internal Revenue Code of 1986, as it may be amended or supplemented from time to time.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Gene Therapy means a product or service for the treatment or prevention of a disease that utilizes ex vivo or in vivo delivery (via viral or nonviral gene transfer methods or systems) of Genetic Material, including any cell incorporating Genetic Material.